Communiqués Cadrenal Therapeutics, Inc.

Actions

CVKD

US1276362076

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 05/10/2026			Varia. 5j.	Varia. 1 janv.
0,9458 ^USD	+0,60%		-17,76%	-86,05%

31/08	Cadrenal Therapeutics annonce une issue favorable suite à sa réunion de type D avec la FDA concernant l'étude d'enregistrement de phase 3 du CAD-1005 dans la thrombocytopénie induite par l'héparine	CI
13/08	Cadrenal Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

21/09	Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference	AQ
03/09	Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference	AQ
31/08	Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia	AQ
13/08	Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process	AQ
03/08	Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation	AQ
21/07	Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation	AQ
13/07	Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress	AQ
01/07	Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules	AQ
24/06	Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress	AQ
18/06	Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease	AQ
15/06	Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026	AQ
03/06	Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event	AQ
19/05	Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026	AQ
07/05	Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA	AQ
30/04	Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)	AQ
01/04	Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results, Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting	AQ
31/03	Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting	AQ
12/03	Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes	AQ
02/03	Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion	AQ
24/02	Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement	AQ
12/01	Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor	AQ
30/12	Cadrenal Therapeutics Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On	AQ
17/12	Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026	AQ
11/12	Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)	AQ
01/12	Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors	AQ